Radiant Biotherapeutics Secures $35 Million to Advance Multabody™ Therapeutics

Industry Partnerships & Commercialization (IP&C) is excited to share that Radiant Biotherapeutics has closed a $35 million USD series A financing co-led by the Bill & Melinda Gates Foundation and Amplitude Ventures.

Radiant Biotherapeutics is a pharmaceutical company built upon the cutting-edge Multabody technology that was researched and developed by Dr. Jean-Philippe Julien at The Hospital for Sick Children (SickKids) and Dr. Bebhinn Treanor at the University of Toronto. By leveraging avidity and multi-specificity, Multabodies offer the potential to deliver next-generation treatment for a variety of hard-to-treat diseases, including cancer, auto-immune and infectious disease.

“I’m thrilled to congratulate Radiant Biotherapeutics on their successful Series A financing,” says Julien. “The Multabody technology that forms the foundation of Radiant Biotherapeutics emerged from years of rigorous research into antibody structures and functions. The exceptional potency of Multabodies could allow us to tackle challenging targets and biological pathways that have eluded conventional antibody approaches, potentially leading to breakthroughs in treating life-threatening diseases.”

This funding will support further development of Multabody therapeutics and advance Radiant Biotherapeutics’ lead drug candidates towards clinical trials.